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lar events and diabetic complications. After 100,000 individuals
are assigned baseline characteristics by sampling UK data, their
baseline risks are predicted and they enter a main module where
these are applied. Periodic updating takes place at doctors’ visits
and other events, such as premature treatment discontinuation
and complications. Resource use, costs and utilities were
obtained from UK databases. All outcomes are discounted at
3.5%/year. RESULTS: After one year treatment, patients on
rimonabant plus diet and exercise lose more than three times the
weight and show greater improvements in other cardiometabolic
risk factors than patients on diet and exercise alone. With diet
and exercise, 633 cardiovascular and 411 microvascular events
are predicted to occur per 1000 patients, over 60 years. Lifetime
costs average ≤5692/patient. One year of rimonabant reduces
cardiovascular and microvascular events by 18 and 10, respec-
tively, with a corresponding reduction in complication costs. Dis-
counted life expectancy increases by 40.2 years, and QALYs by
113.8. Extending treatment to 5 years increases life years and
QALYs gained by a further 38 and 48%, respectively. Extensive
sensitivity analyses, including varying the cost of treatment with
rimonabant, indicate that rimonabant is cost-effective over a
wide range of inputs. CONCLUSIONS: Rimonabant for the
treatment of overweight or obese patients with or without
comorbidities in the UK should be associated with acceptable
cost-effectiveness ratios under a wide range of assumptions.
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OBJECTIVES: The goal of this paper is to test the leader-
follower model in the Argentinean pharmaceutical markets
where patent protection does not apply allowing immediate
entry. METHODS: It was used a leader-follower model where
followers take leader prices to decide their own ones and the
leader strategically incorporates followers’ behavior in its deci-
sion. Two different groups of followers are studied separating
the main three from the rest of the market competitors. The data
used in this study is based in information published by Pharma-
ceutical Markets Argentina (PMA) complemented with indica-
tors of needs and chronicity, obtained through interviews with
physicians and pharmacologists, as well as the list of chemical
entities used in the production of each product, and the nation-
ality of manufactures. RESULTS: From the group of 88 thera-
peutic classes selected, 56 classes kept the same leader during the
period 1988–1995, although just in nine of those cases the ﬁrst
entrant remains as market leader. The cases where market leader
remains the same during the sample period but they were not
necessarily the ﬁrst entrants are deﬁned as loose leadership
markets, while cases of strict leadership are those where ﬁrst
entrants remained as market leaders during the sample period.
CONCLUSIONS: The leader-follower hypothesis is checked and
supported by the data, mirroring the results obtained under a
patent regime. In addition, the lack of patents also raises the
question of difference in behavior among followers. Therefore,
two differentiated groups of followers are studied separating the
main three from the rest of the market competitors.
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Stroke is the leading cause of long term disability worldwide and
a frequent cause of hospital admissions. Considering the popu-
lation aging, stroke is a growing health problem, and is increas-
ingly more costly to manage. Financial burden is caused by the
outcomes of acute stroke and its impact on a variety of health
care resources. OBJECTIVES: To provide referential of health
care resources and direct medical costs of post-acute manage-
ment of stroke per handicap levels within the new French
National Health System context. METHODS: Information pro-
vided by ECIC study on post-acute care delivered to 434 con-
secutive patients with stroke was considered to update data on
the cost of stroke in France. Data on handicap levels assessed 10
days after stroke onset (Rankin scale), medication, rehabilita-
tion, nursing care and ambulatory costs were obtained over 12
and 18 months after the initial acute hospital discharge. With a
NHS perspective, only direct medical costs were considered.
RESULTS: The mean direct medical cost of stroke in France, all
handicap levels considered, is estimated at €15,644 and €17,699
over the ﬁrst 12 and 18 month-periods respectively. At 18
months this cost increases from €8624.5 for patient with Rankin
1 to €39,010.5 for patients with Rankin 5. For patients with
lower handicap (Rankin 1–3) hospitalisation for the acute 
management of stroke is the main driver of costs, whereas for
patients with higher Rankin rehabilitation accounts for 70% of
the total direct medical costs. CONCLUSION: Costs increase by
ﬁve fold between the lowest and the highest handicap level.
Whatever the Rankin considered, costs incurred during the ﬁrst
year represent almost 90% of cost at 18 months. New thera-
peutic advances reducing post-stroke consequences could have a
major impact on health care expenditures.
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OBJECTIVES: While breast cancer has a high incidence world-
wide, there is limited data on treatment costs to help decision-
makers establish the cost-effectiveness of new treatments. This
study’s objective was to determine treatment costs of BC stages
for postmenopausal BC patients in Hungary. METHODS: BC-
speciﬁc resource use items were collected retrospectively on three
cohorts: early breast cancer (EBC), local regional recurrence
(LRR) and metastatic breast cancer (MBC) patients. Data was
obtained from National Health Insurance Fund claims databases
on inpatients, outpatients and pharmaceuticals. Cohorts were
determined using ICD, WHO, ATC, TNM and procedure codes.
Age > 55 served as proxy for postmenopausal status. The ﬁrst
100 relevant patients at each stage entering the Oncology Report
database in 2003 were included and followed for 1 year. Average
annual patient costs with 95% conﬁdence intervals (95%CI)
were established using Hungarian national fee schedules and
reported in euros. RESULTS: The ﬁnal cohort included 87
patients with incident EBC, 79 patients with LRR, and 99
patients receiving active or palliative care for MBC. The fre-
quency of diagnostic and surgical procedures, consultant visits
A200 Abstracts
and prescriptions were summarized in natural units. Average
(95%CI) outpatient, inpatient and drug cost/patient for EBC
patients were estimated to be €1000 (780–1260), €1060 (800–
1300) and €2470 (2100–2840) respectively. For LRR patients the
corresponding ﬁgures were €274 (214–330), €2056 (1470–2600)
and €2160 (1600–2700). In MBC values averaged €260
(210–310), €1150 (850–1550) and €3470 (2800–4150) respec-
tively. Drug costs represented 23%, 40% and 29% of total treat-
ment costs/patient in EBC, LRR and MBC. Costs were highest
in MBC. CONCLUSIONS: Inpatient costs represent the highest
proportion of costs, followed closely by drug costs, possibly due
to relatively low labour costs in Central Europe. These estimates
and underlying treatment patterns will be useful in establishing
the cost-effectiveness of new BC treatments in Hungary and
potentially in the region.
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The Finnish rheumatoid arthritis (RA) combination therapy
(FIN-RACo) trial has shown better efﬁcacy of three disease-
modifying antirheumatic drugs (DMARD) (sulphasalazine,
methotrexate, hydroxychloroquine) and prednisolone compared
to treatment with a single DMARD with or without pred-
nisolone in early RA. Results from FIN-RACo trial show that
early aggressive combination therapy (COMBI) translated into
more remissions and less peripheral joint damage, cervical spine
subluxations, and work disability than therapy with a single
DMARD (SINGLE). OBJECTIVES: Estimate health-related
quality of life (HRQoL) effects of COMBI vs. SINGLE in early
RA. METHODS: A total of 195 patients with early RA were
randomised to COMBI (n = 97) or SINGLE (n = 98) for 2 years.
Thereafter drug treatment became unrestricted. HRQoL was
measured using the 15D instrument. The 15D score of an addi-
tional control sample was used as an estimate of baseline
HRQoL in early RA. RESULTS: The baseline 15D score was
0.856 (95% CI 0.835–0.877; n = 49). The respective ﬁve and
10–11 years 15D scores of COMBI were signiﬁcantly better than
the baseline score (0.929; n = 28, p = 0.000 and 0.901; n = 39,
p = 0.002), in contrast to the corresponding scores of SINGLE
(0.880; n = 34, p = 0.078 and 0.858; n = 30, p = 0.900). The
differences between the COMBI and SINGLE scores at 5 and
10–11 years reached statistical signiﬁcance (p = 0.017 and
0.046), too. CONCLUSION: Early aggressive treatment with
combination of DMARDs is effective also from the viewpoint of
HRQoL. The effect sustains at least up to 10–11 years.
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OBJECTIVES: To evaluate whether it is accepted that commu-
nity pharmacies identify elderly people which are at risk for
osteoporosis and furthermore evaluate the effectiveness of com-
munity pharmacies to motivate identiﬁed patients at risk for
osteoporosis to consult a physician for further diagnosis and
treatment. METHODS: Prospective multi-centre pre-post evalu-
ation in 20 community pharmacies in Southern Germany includ-
ing 765 patients. The screening for risk for osteoporosis 
was based on an adapted osteoporosis risk-questionnaire of 
the “Kuratorium Knochengesundheit e.V.—German Self-Help-
Group”. Patients with identiﬁed risk were consulted with regard
to the disease osteoporosis and recommended to see a physician
for further diagnosis. A maximum of 2 follow-up contacts were
undertaken to receive information whether or not a physician
was seen by the patient. RESULTS: Out of 765 patients, which
were interviewed using the osteoporosis risk-questionnaire 53%
were identiﬁed being at risk and thus were requested to contact
their physician. 66% of these patients did respond to the rec-
ommendation by the community pharmacy and did see a physi-
cian for consultation and further diagnosis of osteoporosis. As a
result, an anti-osteoporotic pharmacotherapy was initiated in
33% of those patients who saw a physician. Overall, 57% of
patients indicated their satisfaction with the service provided by
the pharmacy and 64% agreed that a community pharmacy is
an appropriate place to offer screening for osteoporosis. CON-
CLUSION: Community pharmacies are easy to access by elderly
people and a screening for osteoporosis using an osteoporosis
screening risk-questionnaire was accepted by the majority of
patients.
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OBJECTIVES: How GPs reacted to rofecoxib withdrawal in
Sept. 30, 2004. METHODS: A drug utilisation review was 
performed using data from the electronic records of 1200 French
GPs. All patients aged 65 years and over, suffering from
osteoarthritis and who were prescribed any COX-2 between
January 1st and September 30th 2004 (“reference period”) were
included and compared to themselves in the same period of 2005
(“observation period”). Patients were classiﬁed either as “con-
tinuers” if they received at least one COX-2 prescription in the
“observation period”, or as “stoppers” if not. Discriminatory
factors between the two groups were systematically searched for.
RESULTS: A total of 5589 patients were included. Mean age was
75 years and 68.2% were female. A total of 811 (14.5%) were
classiﬁed as “continuers” and 4778 (85.5%) as “stoppers”.
Among the latter 2914 (61.0%) stopped any NSAID treatment
and 955 (19.9%) received no treatment at all (neither NSAID
